Previous Page  21 / 21
Information
Show Menu
Previous Page 21 / 21
Page Background

Page 51

Notes:

allied

academies

Journal of Timely Topics in Clinical Immunology | Volume 2

July 26-28, 2018 | Moscow, Russia

Immunology

11

th

Annual Congress on

Class IV semaphorin checkpoints regulate allergic asthma

Svetlana P Chapoval

University of Maryland, USA

T

wo class IV semaphorins, Sema4A and Sema4D, belong to a

family of neuron guidance proteins which were also found

to be expressed and function in the immune system. They

both act as immune checkpoints by either directly or indirectly

regulating T cell activation. We defined the in vivo function

of Sema4 molecules in allergic asthma using OVA challenges

of corresponding semaphorin-deficient mice. We found that

Sema4A and 4D molecules play the opposite roles in disease.

Whereas Sema4A-/- mice demonstrated a selective increase

in airway eosinophilia accompanied by bronchial epithelial cell

hyperplasia as compared toWTmice, these asthma parameters

weredecreased inSema4D-/-mice. Theenhanced inflammatory

response in Sema4A-/- mice was associated with a selective

increase in bronchoalveolar lavage IL-13 content, augmented

airway hyperreactivity (AHR), and lower Treg cell numbers. In

contrast, lower Th2 cytokine levels and higher number of Treg

cells were found in the lungs of Sema4D-/- mice, whereas AHR

was not affected. Allergen-primed Sema4A-/- CD4+ T cells

were more effective in transferring Th2 response to naive mice

as compared with WT CD4+ T cells. T-cell proliferation and IL-

13 productions were upregulated in OVA₃₂₃₋₃₃₉-restimulated

Sema4A-/- cell cultures and downregulated in Sema4D-/-

cultures as compared to similarly challenged WT cells.

Generatedbonemarrowchimeras showedanequal importance

of both lung-resident cell and inflammatory cell Sema4A

expression in optimal disease regulation. These data provide a

new insight into Sema4 biology and define Sema4 molecules

as important regulators of Th2-driven lung pathophysiology

and prospective targets for disease immunotherapy.

e:

SChapoval@som.umaryland.edu